Western Branch Diesel Charleston Wv
Activate's platform updates will enable study teams to version control study documents and automate their distribution and tracking across countries and sites. Unilife CEO, Alan Shortall discusses his company's unique business model, transformational approach to the market, and his thoughts on how to move forward. Resverlogix announces appointment of new chief scientific officer press release. "Despite the availability of a vaccine, HBV remains a serious global public health problem with more than 250 million people worldwide living with chronic infection, " said Gregory Mayes, Ajinomoto Bio-Pharma Services & Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic. Amy Grogg, Senior Vice President of Strategy and Commercialization at AmerisourceBergen Specialty Group provides her perspective on the barriers orphan drug manufacturers face and the solutions available to them through strategic partnerships with distributors. The application, Nasal Spray to Prevent the Transmission of Covid-19, discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies.
"This is an important step forward in the battle against the many cancers that are driven by a p53 mutation, " said David Mack, PhD, Ocuphire Pharma, Inc. recently announced the enrollment of the first patient in its MIRA-2 (NCT04620213) Phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol to reverse pharmacologically induced mydriasis. Eyenovia, Inc. recently announced that the company successfully completed a Type A meeting with the US FDA related to the refiling of the NDA for MydCombi. 75 million is an upfront payment, Halozyme Therapeutics, Inc. recently announced that the US FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase II trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer, permitting the study to resume under a revised protocol. Resverlogix announces appointment of new chief scientific officer at hepagene therapeutics inc suzhou. The funding will be used to support the company's clinical development plans; the funding is sufficient to advance the company's lead product, the Glatiramer Acetate (GA) Depot, a once-every-4-weeks injection, currently at Phase II, up to the initiation of the single pivotal Phase III needed for registration. The study results suggested vonapanitase may improve both fistula use for hemodialysis and secondary patency (time to fistula abandonment), which are the co-primary endpoints in Proteon's ongoing Phase 3 PATENCY-2 clinical trial. The Altitude Trial is a double-blind, randomized, placebo-controlled crossover study, designed to evaluate the effects of TSC on maximal oxygen consumption, or VO2, and partial pressure of arterial blood oxygen, or PaO2, in normal healthy volunteers subjected to incremental levels of physical exertion while exposed to hypoxic and hypobaric conditions at a simulated altitude of 15, 000 feet above sea level. VTv Therapeutics & Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development & Commercialization of Cancer Treatment. The additional capacity reinforces BioPharma Solutions' leadership position as one of the largest capacity CMOs for freeze-dried (lyophilized) cytotoxic (having a toxic effect on cells) parenterals. Employing over 45 scientific and quality personnel, CSL Behring LLC recently announced its affiliate company, CSL Behring AG, of Bern, Switzerland, and Enable Injections, LLC, of Franklin, OH, have signed a long-term development agreement for a new and innovative drug delivery system intended to improve the comfort, convenience, and treatment compliance for patients with rare and serious diseases. Aptar Pharma has worked closely with the Swiss-German-based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy, and maintaining product stability on the ophthalmic spray device. Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility.
As previously announced, Generex engaged the University of Toronto's Center for Molecular Design and Pre-formulations (CMDP) () through the University Health Network () with the goal of enhancing the Generex Oral-lyn formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of sprays required to achieve effective prandial metabolic control for patients with diabetes. Attune Pharmaceuticals, Inc. recently announced the completion of a $23 million Series B financing. Resverlogix (TSX:RVX) focuses drug development on COVID-19. MultiCell Technologies, Inc. and Genisphere LLC will collaborate on the development of targeted MCT-485 nanoparticle therapeutics for the treatment of liver cancer. The name change reflects the unified company's commitment to providing its large and small molecule clients accessibility to a broader range of service offerings.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently announced they have entered into an agreement with Firefly BioWorks to be a global distributor of the SmartRNAplex microRNA (miRNA) profiling assay. With over 50 generic and innovator pharma clients, Navitas Life Sciences has over 10 years of proven expertise. With the positive recommendation, the final 12 patients in this second cohort are now cleared for enrollment. Resverlogix announces appointment of new chief scientific officer перевод. Luminita Moraru, MSC, MRSC, says the medical devices industry is in continuous growth, and the development of new reliable and accurate approaches in order to assess the safety of the products should constantly be reviewed. Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.
Specifically: Sanofi will obtain global development and commercialization rights to fitusiran, an investigational RNAi therapeutic, currently in development for the treatment of people with hemophilia A and B. The company expects the study to remain open and continue enrolling patients until the product potentially becomes available on the market and believes it remains on target to file a biologic license application (BLA) by the end of 2019 under the breakthrough therapy designation (BTD) the company previously received from the FDA. Voyager Therapeutics, Inc. recently announced a research collaboration with CHDI Foundation, Inc. (CHDI) to advance Voyager's VY-HTT01 program, an adeno-associated virus (AAV)-mediated gene-silencing therapy for Huntington's disease. RVX News Today | Why did Resverlogix stock go down today. Xalud has recently presented promising data from three of its previously completed Phase 1b/2a studies in the same indication in a poster presentation at the Osteoarthritis Research Society International (OARSI) Virtual World Congress held on April 29-May 1, 2021. With 20% CAGR for the last 5 years, it is one of the fastest growing companies in the $5. The strong growth in the number of complex drugs, new therapeutic approaches and technologies, pricing issues and…. The new financing includes additional equity investment from a new investor and all of Blend's existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.